Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
Launched by ENDEAVOR HEALTH · Mar 20, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how ultrasound exams can help predict the risk of excessive bleeding after delivery, known as postpartum hemorrhage. While many women experience heavy bleeding immediately after giving birth, this study is focused on identifying issues that might cause bleeding between 1.5 to 24 hours afterward. By performing ultrasound exams shortly after delivery, researchers hope to find signs that could indicate whether a woman is at risk for this type of bleeding.
To participate, women must be at least 37 weeks pregnant and planning to deliver at Endeavor Health. They should be able to speak English and be in early labor (less than 6 cm dilated without an epidural or less than 8 cm with an epidural) when they consent to join the study. If they agree to participate, researchers will collect information about their medical history and details of their delivery, along with ultrasound results. This information will help understand the connection between ultrasound findings and the risk of bleeding, ensuring better care for new mothers.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Currently pregnant and planning to deliver at Endeavor Health \>37 weeks gestational age
- • English speaking
- • Labor \<6cm dilated at time of consent without epidural
- • Labor \<8cm dilated at time of consent with epidural
- Exclusion Criteria:
- • Preterm delivery
- • Non-English speaking
- • Any conditions that impairs potential participants decision making
About Endeavor Health
Endeavor Health is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative studies. With a focus on fostering collaboration among healthcare professionals, researchers, and patients, Endeavor Health specializes in the development and execution of clinical trials across various therapeutic areas. The organization is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the integrity of its research while prioritizing participant safety and well-being. By leveraging cutting-edge technology and a patient-centric approach, Endeavor Health aims to drive breakthroughs in healthcare and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Evanston, Illinois, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported